Linked Life Data

7025719

Source:http://linkedlifedata.com/resource/pubmed/id/7025719

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7025719rdf:typepubmed:Citationlld:pubmed
pubmed-article:7025719lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:7025719lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:7025719lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:7025719lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:7025719lifeskim:mentionsumls-concept:C0042682lld:lifeskim
pubmed-article:7025719lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:7025719lifeskim:mentionsumls-concept:C1521750lld:lifeskim
pubmed-article:7025719lifeskim:mentionsumls-concept:C0086960lld:lifeskim
pubmed-article:7025719lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:7025719lifeskim:mentionsumls-concept:C1554217lld:lifeskim
pubmed-article:7025719pubmed:issue4lld:pubmed
pubmed-article:7025719pubmed:dateCreated1981-11-22lld:pubmed
pubmed-article:7025719pubmed:abstractTextEighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine with either high dose (120 mg/m2 of body surface area) or low dose (60 mg/m2) cisplatin. All patients had measurable disease and had not previously received chemotherapy. The response rate was similar with both treatments (43% complete and partial remission rate), but the high dose cisplatin regimen was superior to the low dose in median duration of response (12 versus 5.5 months; p = 0.05) and in median survival for responding patients (21.7 versus 10 months; p = 0.02). Myelosuppression was generally not a treatment problem; peripheral neuropathy and moderate azotemia were the major dose-limiting toxicities. With improved survival and response rates over those reported for conventional regimens, this combination of new agents supports the approach of new drug investigation in patients with lung cancer and the importance of the incorporation of active new agents into initial chemotherapy regimens.lld:pubmed
pubmed-article:7025719pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025719pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025719pubmed:languageenglld:pubmed
pubmed-article:7025719pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025719pubmed:citationSubsetAIMlld:pubmed
pubmed-article:7025719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025719pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025719pubmed:statusMEDLINElld:pubmed
pubmed-article:7025719pubmed:monthOctlld:pubmed
pubmed-article:7025719pubmed:issn0003-4819lld:pubmed
pubmed-article:7025719pubmed:authorpubmed-author:YoungC WCWlld:pubmed
pubmed-article:7025719pubmed:authorpubmed-author:GolbeyR BRBlld:pubmed
pubmed-article:7025719pubmed:authorpubmed-author:KelsenD PDPlld:pubmed
pubmed-article:7025719pubmed:authorpubmed-author:MartiniNNlld:pubmed
pubmed-article:7025719pubmed:authorpubmed-author:GrallaR JRJlld:pubmed
pubmed-article:7025719pubmed:authorpubmed-author:CasperE SESlld:pubmed
pubmed-article:7025719pubmed:authorpubmed-author:BraunD WDWJrlld:pubmed
pubmed-article:7025719pubmed:authorpubmed-author:DukemanM EMElld:pubmed
pubmed-article:7025719pubmed:issnTypePrintlld:pubmed
pubmed-article:7025719pubmed:volume95lld:pubmed
pubmed-article:7025719pubmed:ownerNLMlld:pubmed
pubmed-article:7025719pubmed:authorsCompleteYlld:pubmed
pubmed-article:7025719pubmed:pagination414-20lld:pubmed
pubmed-article:7025719pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:meshHeadingpubmed-meshheading:7025719-...lld:pubmed
pubmed-article:7025719pubmed:year1981lld:pubmed
pubmed-article:7025719pubmed:articleTitleCisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.lld:pubmed
pubmed-article:7025719pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7025719pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7025719pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7025719pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:7025719pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025719lld:pubmed